Jci_page_head_homepage_01 Jci_page_head_homepage_02
Cullen M. Taniguchi, Kohjiro Ueki, C. Ronald Kahn
Published in Volume 115, Issue 3
J Clin Invest. 2005; 115(3):718–727 doi:10.1172/JCI23187
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4

Significant defects in Akt activation and downstream targets of Akt in mice treated with IRS1U6 and IRS2U6. (A) Insulin-stimulated liver lysates from mice treated with RNAi adenovirus blotted with anti-phospho Akt (S473) antibody (top panel). Blots were then stripped and reprobed for total Akt (bottom panel). The blot is representative of 3 independent experiments. (B) Akt kinase activity was measured in Akt immunoprecipitates using Crosstide as a substrate (56). Bars represent mean ± SEM (n = 3). *P < 0.01 dual treatment vs. siGFP. (C) Insulin-stimulated liver lysates from mice treated with RNAi adenovirus blotted with antibodies against phospho-Foxo1 (S256) or phopsho-MAPK (T202/Y204). The blots for the phosphorylated proteins were then stripped and reprobed with antibodies for total Foxo1 or total MAPK. These Western blots are representative of 3 independent experiments.